Genetic deletion of vesicular monoamine transporter-2 (VMAT2) reduces dopamine transporter activity in mesencephalic neurons in primary culture

Neurochemistry International

Volumn 51, Issue 2-4 SPEC. ISS., 2007, Pages 237-244

  Yamamoto, Hideko ^a   Kamegaya, Etsuko ^a   Hagino, Yoko ^a   Imai, Kazuhide ^b   Fujikawa, Akihiro ^c   Tamura, Kohei ^a,d   Enokiya, Tomoyuki ^d   Yamamoto, Toshifumi ^a,d   Takeshima, Takao ^e   Koga, Hisashi ^b   Uhl, George R ^f   Ikeda, Kazutaka ^a   Sora, Ichiro ^g  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b KAZUSA DNA RESEARCH INSTITUTE   (Japan)

^c NATIONAL INSTITUTE FOR BASIC BIOLOGY   (Japan)

^d YOKOHAMA CITY UNIVERSITY   (Japan)

^e TOTTORI UNIVERSITY   (Japan)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

DAT; mKIAA gene; Primary brain stem culture; VMAT2 KO

Indexed keywords

DOPAMINE TRANSPORTER; TYROSINE 3 MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL FUNCTION; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; FEMALE; FETUS; GENE DELETION; GENOTYPE; KNOCKOUT MOUSE; MALE; MESENCEPHALON; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; WILD TYPE;

ANIMALS; CELL DEATH; CELLS, CULTURED; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOWN-REGULATION; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; MALE; MESENCEPHALON; MICE; MICE, KNOCKOUT; NEURONS; PRESYNAPTIC TERMINALS; SYNAPTIC TRANSMISSION; TYROSINE 3-MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORT PROTEINS;

MUS;

EID: 34547449724     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2007.06.022     Document Type: Article

References (26)

1. Boja J.W., McNeill R.M., Lewin A.H., Abraham P., Carroll F.I., and Kuhar M.J. Selective dopamine transporter inhibition by cocaine analogs. Neuroreport 3 (1992) 984-986
2. Croft B.G., Fortin G.D., Corera A.T., Edwards R.H., Beaudet A., Trudeau L.E., and Fon E.A. Normal biogenesis and cycling of empty synaptic vesicles in dopamine neurons of vesicular monoamine transporter 2 knockout mice. Mol. Biol. Cell. 16 (2005) 306-315
3. Erickson J.D., Eiden L.E., and Hoffman B.J. Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 10993-10997
4. Erickson J.D., and Eiden L.E. Functional identification and molecular cloning of a human brain vesicle monoamine transporter. J. Neurochem. 61 (1993) 2314-2317
5. Fon E.A., Pothos E.N., Sun B.C., Killeen N., Sulzer D., and Edwards R.H. Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron 19 (1997) 1271-1283
6. Fumagalli F., Gainetdinov R.R., Wang Y.M., Valenzano K.J., Miller G.W., and Caron M.G. Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J. Neurosci. 19 (1999) 2424-2431
7. Gainetdinov R.R., Fumagalli F., Wang Y.M., Jones S.R., Levey A.I., Miller G.W., and Caron M.G. Increased MPTP neurotoxicity in vesicular monoamine transporter knockout mice. J. Neurochem. 70 (1998) 1973-1978
8. Giros B., Jaber M., Jones S.R., Wightman R.M., and Caron M.G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379 (1996) 606-612
9. Henry J.-P., Botton D., Sagne C., Isambert M.-F., Desnos C., Blanchard V., Raisman-Vozari R., Krejci E., Massoulie J., and Gasnier B. Biochemistry and molecular biology of the vesicular monoamine transporter from chromaffin granules. J. Exp. Biol. 196 (1994) 251-262
10. Johnson R.G. Accumulation of biological amines into chromaffin granules: a model for hormone and neurotransmitter transport. Physiol. Rev. 68 (1988) 232-307
11. + toxicity encodes a vesicular amine transporter. Cell 70 (1992) 539-551
12. Loder M.K., and Melikian H.E. The dopamine transporter constitutively internalizes and recycles in a protein kinase C-regulated manner in stably transfected PC12 cell lines. J. Biol. Chem. 278 (2003) 22168-22174
13. Metzger R.R., Brown J.M., Sandoval V., Rau K.S., Elwan M.A., Miller G.W., Hanson G.R., and Fleckenstein A.E. Inhibitory effect of reserpine on dopamine transporter function. Eur. J. Pharmacol. 456 (2002) 39-43
14. Miller G.W., Staley J.K., Heilman C.J., Perez J.T., Mash D.C., Rye D.B., and Levey A.I. Immunochemical analysis of dopamine transporter protein in Parkinson's disease. Ann. Neurol. 41 (1997) 530-539
15. Mooslehner K.A., Chan P.M., Xu W., Liu L., Smadja C., Humby T., Allen N.D., Wilkinson L.S., and Emson P.C. Mice with very low expression of the vesicular monoamine transporter 2 gene survive into adulthood: potential mouse model for parkinsonism. Mol. Cell. Biol. 21 (2001) 5321-5331
16. Mortensen O.V., and Amara S.G. Dynamic regulation of the dopamine transporter. Eur. J. Pharmacol. 479 (2003) 159-170
17. Pristupa Z.B., McConkey F., Liu F., Man H.Y., Lee F.J., Wang Y.T., and Niznik H.B. Protein kinase-mediated bidirectional trafficking and functional regulation of the human dopamine transporter. Synapse 30 (1998) 79-87
18. - cotransporter. Nature 387 (1997) 409-413
19. 3 cotransporters in rat brain: expression in glia, neurons, and choroid plexus. J. Neurosci. 20 (2000) 6839-6848
20. Shimoda K., Sauvt Y., Marini A., Schwartz J.P., and Commissiong J.W. A high percentage yield of tyrosine hydroxylase-positive cells from rat E 14 mesencephalic cell culture. Brain Res. 586 (1992) 19-33
21. Takahashi N., Miner L.L., Sora I., Ujike H., Revay R.S., Kostic V., Jackson-Lewis V., Przedborski S., and Uhl G.R. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 9938-9943
22. Wang Y.M., Gainetdinov R.R., Fumagalli F., Xu F., Jones S.R., Bock C.B., Miller G.W., Wightman R.M., and Caron M.G. Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 19 (1997) 1285-1296
23. Wilson J.M., Levey A.I., Rajput A., Ang L., Guttman M., Shannak K., Niznik H., Hornykiewicz O., Pifl C., and Kish S. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 47 (1996) 718-726
24. Yamakawa H., Yokoyama S., Hiran T., Kitamura H., and Ohara O. A simple and robust method for preparation of cDNA nylon microarrays. DNA Res. 11 (2004) 353-360
25. Yamamoto H., Yamamoto T., Sagi N., Klenerova V., Goji K., Kawai N., Baba A., Takamori E., and Moroji T. Sigma ligands indirectly modulate the NMDA receptor-ion channel complex on intact neuronal cells via sigma 1 site. J. Neurosci. 15 (1995) 731-736
26. Yamamoto H., Imai K., Takamatsu Y., Kamegaya E., Kishida M., Hagino Y., Hara Y., Shimada K., Yamamoto T., Sora I., Koga H., and Ikeda K. Methamphetamine modulation of gene expression in the brain: analysis using customized cDNA microarray system with the mouse homologues of KIAA genes. Brain Res. Mol. Brain Res. 137 (2005) 40-46